Jun 2026 (Q2 FY26) — Aug 13, 2026
ADC Therapeutics Q2 FY26 — ZYNLONTA Performance and Pipeline Updates
Read the full callADC Therapeutics (ADCT) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
ADC Therapeutics earnings: last reported Thu, 13 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 19.2 | +2.2% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | -132.0 | +102.3 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | -16.6 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Price
$1.44 +2.86% · +$0.04
Performance −64.7% 1Y
1Y: $4.08 on 17 Oct 2025 → $1.44. High $4.88 (11 Mar 2026), low $0.96 (20 Aug 2026).
- Previous close
- $1.4
- 52-week range
- $0.96 – $4.88
- One year
- −66.43%
Overview
- Symbol
- ADCT
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
ADC Therapeutics earnings calls (ADCT)
Financials
What the filings say
Net profit, year on year: +71% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 18 | 17 | 23 | 19 | 16 | 23 | 21 | 19 |
| Expenses | 54 | 49 | 51 | 63 | 47 | 41 | 46 | 45 |
| Operating profit | -36 | -32 | -28 | -44 | -31 | -18 | -25 | -25 |
| Operating margin | −192.6% | −191.8% | −123.6% | −234.3% | −188.5% | −77.7% | −121.1% | −132.0% |
| Other income | -8 | 1 | -10 | -11 | -10 | 11 | -8 | 9 |
| Interest | 13 | 12 | 12 | 13 | 13 | 13 | 12 | 14 |
| Profit before tax | -44 | -31 | -38 | -55 | -41 | -7 | -33 | -17 |
| Tax rate | −0.2% | 1.0% | −0.4% | −2.3% | 0.0% | 5.9% | 0.0% | 0.0% |
| Net profit | -44 | -31 | -39 | -57 | -41 | -6 | -33 | -17 |
| EPS ($ per share) | -0.42 | — | -0.36 | -0.50 | -0.30 | — | -0.21 | -0.11 |
| Line item | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Equity capital | 7 | 7 | 8 | 11 |
| Reserves | -1,095 | -1,335 | -1,493 | -1,636 |
| Total liabilities | 411 | 503 | 525 | 509 |
| Fixed assets | 3 | 6 | 5 | 0 |
| Total assets | 491 | 355 | 322 | 323 |
| Line item | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Cash from operations | -138 | -119 | -124 | -141 |
| Cash from investing | -1 | -3 | -1 | 0 |
| Cash from financing | -1 | 74 | 97 | 151 |
| Capital expenditure | -1 | -3 | -1 | -0 |
| Free cash flow | -139 | -122 | -125 | -141 |
Insider filings
39 filings between Dec 6, 2025 and Jun 30, 2026.
Open market
decisions to buy or sellPurchases
None
No insider bought shares.
Sales
$19.64M
6 sales by 1 insider
Compensation
not trading decisions- 16
- Award — granted as compensation
- 17
- Tax withheld — shares kept back by the company to cover tax
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Redmile Group, LLC | — | $19.64M | Apr 2, 2026 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Jun 30, 2026 | Carmona Jose Chief Financial Officer | Award | 203,700 | $0 |
| Jun 30, 2026 | GRAHAM PETER J Chief Legal Officer | Award | 221,100 | $0 |
| Jun 30, 2026 | MALLIK AMEET Chief Executive Officer | Award | 675,000 | $0 |
| Jun 30, 2026 | Zaki Mohamed Chief Medical Officer | Award | 213,900 | $0 |
| Jun 3, 2026 | Azelby Robert Director | Tax withheld | 12,600 | $38.8K |
| Jun 3, 2026 | COUGHLIN TIMOTHY Director | Tax withheld | 12,600 | $38.8K |
| Jun 3, 2026 | BIZZARI JEAN-PIERRE Director | Tax withheld | 12,600 | $38.8K |
| Jun 3, 2026 | Hug Peter Director | Tax withheld | 2,156 | $6.6K |
| Jun 3, 2026 | Monges Viviane Director | Tax withheld | 2,596 | $8.0K |
| Jun 3, 2026 | Sandor Victor Director | Tax withheld | 12,600 | $38.8K |
| Jun 3, 2026 | Squarer Ron Director | Tax withheld | 15,196 | $46.8K |
| Jun 1, 2026 | BIZZARI JEAN-PIERRE Director | Award | 45,000 | $0 |
| Jun 1, 2026 | Sandor Victor Director | Award | 45,000 | $0 |
| Jun 1, 2026 | Monges Viviane Director | Award | 45,000 | $0 |
| Jun 1, 2026 | Squarer Ron Director | Award | 45,000 | $0 |
| Jun 1, 2026 | Hug Peter Director | Award | 45,000 | $0 |
| Jun 1, 2026 | Azelby Robert Director | Award | 45,000 | $0 |
| Jun 1, 2026 | COUGHLIN TIMOTHY Director | Award | 45,000 | $0 |
| Apr 2, 2026 | Redmile Group, LLC 10% owner | Sale | 2,634,506 | $8.64M |
| Apr 2, 2026 | Redmile Group, LLC 10% owner | Sale | 2,529,491 | $8.29M |
| Apr 1, 2026 | Redmile Group, LLC 10% owner | Sale | 169,265 | $643.0K |
| Apr 1, 2026 | Redmile Group, LLC 10% owner | Sale | 162,517 | $617.4K |
| Mar 31, 2026 | Redmile Group, LLC 10% owner | Sale | 188,407 | $706.9K |
| Mar 31, 2026 | Redmile Group, LLC 10% owner | Sale | 196,229 | $736.3K |
| Feb 13, 2026 | MALLIK AMEET Chief Executive Officer | Award | 900,000 | $3.59M |
| Feb 13, 2026 | MALLIK AMEET Chief Executive Officer | Tax withheld | 103,231 | $411.9K |
| Feb 13, 2026 | Carmona Jose Chief Financial Officer | Award | 271,600 | $1.08M |
| Feb 13, 2026 | Carmona Jose Chief Financial Officer | Tax withheld | 25,880 | $103.3K |
| Feb 13, 2026 | GRAHAM PETER J Chief Legal Officer | Award | 294,800 | $1.18M |
| Feb 13, 2026 | Zaki Mohamed Chief Medical Officer | Tax withheld | 24,603 | $98.2K |
| Feb 13, 2026 | GRAHAM PETER J Chief Legal Officer | Tax withheld | 33,294 | $132.8K |
| Feb 13, 2026 | Kallebo Lisa Michelle Chief Accounting Officer | Tax withheld | 5,433 | $21.7K |
| Feb 13, 2026 | Zaki Mohamed Chief Medical Officer | Award | 285,200 | $1.14M |
| Feb 13, 2026 | Kallebo Lisa Michelle Chief Accounting Officer | Award | 62,900 | $251.0K |
| Dec 6, 2025 | Kallebo Lisa Michelle Chief Accounting Officer | Tax withheld | 7,140 | $23.5K |
| Dec 6, 2025 | Carmona Jose Chief Financial Officer | Tax withheld | 53,236 | $175.1K |
| Dec 6, 2025 | GRAHAM PETER J Chief Legal Officer | Tax withheld | 49,508 | $162.9K |
| Dec 6, 2025 | Zaki Mohamed Chief Medical Officer | Tax withheld | 41,068 | $135.1K |
| Dec 6, 2025 | MALLIK AMEET Chief Executive Officer | Tax withheld | 233,146 | $767.1K |
| Jun 13, 2025 | Azelby Robert Director | Tax withheld | 12,600 | $45.1K |
| Jun 13, 2025 | BIZZARI JEAN-PIERRE Director | Tax withheld | 12,600 | $45.1K |
| Jun 13, 2025 | Hug Peter Director | Tax withheld | 2,144 | $7.7K |
| Jun 13, 2025 | Monges Viviane Director | Tax withheld | 2,584 | $9.3K |
| Jun 13, 2025 | Sandor Victor Director | Tax withheld | 12,600 | $45.1K |
| Jun 13, 2025 | Squarer Ron Director | Tax withheld | 15,184 | $54.4K |
| Jun 3, 2025 | Squarer Ron Director | Award | 40,000 | $0 |
| Jun 3, 2025 | Monges Viviane Director | Award | 40,000 | $0 |
| Jun 3, 2025 | Hug Peter Director | Award | 40,000 | $0 |
| Jun 3, 2025 | BIZZARI JEAN-PIERRE Director | Award | 40,000 | $0 |
| Jun 3, 2025 | Azelby Robert Director | Award | 40,000 | $0 |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for ADC Therapeutics SA
Free account. Everything above stays public.
Write why you follow ADC Therapeutics SA and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading